Verastem Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Yeah, it's been good. We can get some investors we don't see all the time here, which is nice.
All right, great. Good afternoon, everyone. Thank you, those of you who've joined in the room and on the phone line as well. My name is Faisal Khurshid, senior biotech analyst at Jefferies. Really pleased to have with us today the management team of Verastem Oncology. Especially pleased to have Michael Bailey in, I think, your first kind of real public showing as the CEO?
Yeah, back in the saddle.
All right. Awesome. Well, Michael, why don't we just start there? I would love if you can just kind of give a little bit of an intro to yourself, the company, and really kind of what encouraged you to take the role.
Yeah. Thank you very much, Faisal, and thanks for having me here. I am really looking forward to this discussion and individual discussions with investors. As far as my background, I am largely business development, kind of commercial type history. I have been with companies like Genentech, AVEO, ImClone. Most recently with ImClone as their CEO for about 11 years, that subsequently sold to LG Chem. Spent about three years with them after that, working on the integration. To your other part of the question, what got me excited about Verastem? I joined the Verastem board in June timeframe, and fast-forward to October 14th, the world really changed for Verastem. As I looked at it as a board member, and then given consideration for taking the seat and the CEO, there was kind of three things that really changed on October 14th. One, a wealth of data.
Two, a really successful financing. Three, obviously the opportunity for me to take over as CEO, and I will kind of unpack each one of those things. The data, and we will spend a little bit more time on the VS-7375 data, really kind of positioned us very clearly as a best-in-class G12D inhibitor. I think, one of the questions with RevMed and all the excitement that RAS and Q has brought to the table, and appropriate excitement, is that if you looked at the G12D, which the FDA pulled back the curtain, if you will, their activity was a little less than the G12D, notably because that is a tougher population. Our data in G12D looked really solid that we presented on that day. The other thing I think is really exciting for me and others is the complete responses.
We are seeing single-agent complete responses that I think will be game-changing for this whole space. The second thing I think is the financing. A $250 million raise, very strong demand going into that, I think shows an investor sentiment that is changing and realizing the potential for us kind of going forward. The last thing I think is obviously my leadership and my background being more business development and commercial. What that does really for us is it gives us more optionality. Can we commercialize this by ourselves? Are there BD or partnership opportunities? I think all of those things are on the table.
Got it. I want to touch on both of those points, and we have Dr. John Pachter here as well, so we will definitely get into the G12D data. Before we do that, Michael, on that last point that you made on partnership, obviously you are sitting on something very interesting and valuable here with respect to the data that you have generated, and also the robust development plan that you have laid out with plans across all three major indications of pancreatic, colorectal, and lung. How do you think about this from a partnership and value-driving perspective with respect to what does that look like, what does the right timing look like? Just given your background and experience here, would love your comments on that.
Yeah. It is a great question, and the simple answer is not really sure at this point. It is a very rapidly evolving space, and as a company, I think it is really critical to drive shareholder value, to really entertain every single option that is out there. Clearly there is a lot of interest, not only from investors, also from partners. But look at the best, if the best valuation that we can achieve is commercializing ourselves, we need to think about it as what we are really doing here. We would be potentially launching as the first G12D in pancreatic. When you think about it that way, it is a little more manageable than if you take that whole scope of all the opportunities in front of us. That is a little daunting. Just keep in mind, we have to do this stepwise.
Got it. Okay. Makes sense. Let us jump into the data itself then. John, I want to give you an opportunity here to talk about, in terms of what you guys have presented, you are putting up some of the best response rates seen for a G12D selective inhibitor. Can you remind us what has enabled that from kind of the basis of the molecule itself?
Yeah, I would love to. I think a few pillars to that. I think first of all, the dual ON/OFF inhibition, which is really important. G12D is mostly in the ON state, but it can go kind of hide out in the OFF state and come back and cycle, and to be able to bind it no matter where it lives is great. It has to be very potent and really equipotent. Ours is about 15 picomolar for both of those states. There is a long residence time, which also really predicted. We saw all this before we saw any clinical data, mind you, and we predicted that it was a good shot at having the best efficacy for patients with KRAS G12D cancers. So the long residence time or slow off rate, about a 24-hour residence time. The third point is it is extremely selective for KRAS G12D.
I think it lets us dose up with good tolerability. KRAS G12D is not responsible for any normal functions in your body, so there are no side effects that would be expected from hitting the target directly, and so that selectivity is really key. Then finally, and I think this has been underestimated, as I look at the RAS space, I think that most inhibitors can not get to maximal inhibition of target for a couple of reasons, depending on the agent. There are some agents where pharmacologically you dose. There is one I am thinking of, you dose at 600, 900, 1,200, you get basically the same exposure. It is flat. It is just a property of the molecule, and that makes it hard to fully hit the target. When you look at waterfalls, you might see on the left side of the waterfall some tumor growth as the best response.
If you're fully hitting the target as we are, we're not seeing that tumor growth as best response when we go up to 900, which is our go-forward dose. In the case of other agents like the pan-RAS inhibitors, pharmacologically, they might be able to achieve better exposure to fully hit the target, but they're limited by the safety profile.
Got it. I want to talk about that, what you just raised on the safety profile, and I'm going to raise this question in sort of a nuanced way, so bear with me. So obviously, your China partner, GenFleet, they've been kind of a half step to one step ahead in terms of data generation. They showed a phase I profile that had this impressive efficacy, but had a good amount of safety baggage with it. You've now shared, as of October, a full set of your phase I data from the U.S. study that looked quite a bit better on the safety profile. For investors, where they worry a little bit about is this kind of a spurious finding? Is this related to limited follow-up?
How can we actually believe that the safety profile is as good as what you're seeing in the U.S. study? What would you say to kind of convince investors of that?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
